Please login to the form below

Not currently logged in
Email:
Password:

Nuedexta

This page shows the latest Nuedexta news and features for those working in and with pharma, biotech and healthcare.

Otsuka presses on with Alzheimer’s agitation drug

Otsuka presses on with Alzheimer’s agitation drug

The investigational therapy is a new formulation of the active ingredients in Otsuka/Avanir's already-marketed Nuedexta (deudextromethorphan hydrobromide/quinidine sulphate) product.

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 9, 500. Avanir Pharmaceuticals / Otsuka Pharmaceutical. Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics